psychedelics-investing Nirvana Life Sciences Inc. announces agreement to acquire the licensed distributor of a Patented, WHO approved, herbal treatment for opiate addiction
psychedelics-investing Nirvana Life Sciences Inc. Announces the Appointment of Sheldon Inwentash to the Board of Directors
psychedelics-investing Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives
psychedelics-investing Nirvana Life Sciences Inc. Announces a Method for Producing MDMA that Reduces Manufacturing Time by Two Thirds
psychedelics-investing Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs
psychedelics-investing Nirvana Life Sciences Announces Approval To Build Vancouver Facility From Health Canada
psychedelics-investing Nirvana Life Sciences announces filing of Patent for novel isolation of 4-PO-Psilocin Prodrug Compound
psychedelics-investing Nirvana Life Sciences Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study
Centerra Gold Receives Permit Amendments for Mount Milligan to Continue Operations Through 2035; Meets Expedited Schedule as Per Commitment from the Province of British Columbia
Centerra Gold Receives Permit Amendments for Mount Milligan to Continue Operations Through 2035; Meets Expedited Schedule as Per Commitment from the Province of British Columbia
